MY ACCOUNT | NEWSLETTER |

Characterization of the myocardial and renal renin-angiotensin system in normal cats and cats with hypertrophic cardiomyopathy.

Clinical evidence update from Journal of veterinary internal medicine


Clinical Context

Peer-reviewed veterinary literature continues to shape everyday decision-making for feline patients, especially when new evidence clarifies diagnosis, treatment selection, monitoring, or clinical outcomes.

What the Study Evaluated

A study published in Journal of veterinary internal medicine in 2026 evaluated characterization of the myocardial and renal renin-angiotensin system in normal cats and cats with hypertrophic cardiomyopathy..

Key Findings

The tissue renin-angiotensin system (RAS) has not been characterized in cats. To quantify RAS enzyme activity and angiotensin peptide (AP) concentrations in myocardial and renal tissue obtained at necropsy from healthy cats and cats with hypertrophic cardiomyopathy (HCM). A convenience sample of 17 adult purpose-bred cats, euthanized under other study protocols, with echocardiographically normal hearts (n = 8) or American College of Veterinary Internal Medicine stage B1 (n = 6) or C (n = 3) HCM. Prospective study. Tissues were incubated with spiked angiotensin I (AngI) or II (AngII) under control and inhibitor conditions to assess relative...

Why It Matters for Veterinary Professionals

For veterinary professionals, the practical value of this work lies in how the findings may support more structured clinical assessment, clearer monitoring, and more informed decisions for feline patients.

Practical Interpretation

The results should be interpreted in the context of the study design, population, inclusion criteria, and clinical setting. Application in practice should consider patient-specific risk factors, available diagnostics, local standards of care, and clinician judgment.

Clinical Takeaway

Overall, the study adds useful evidence for clinicians seeking to align daily practice with current veterinary research while maintaining a balanced, case-by-case approach.

Read the full article here.

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Year-round threat: 2026 Pet Parasite Forecast shows rising tick risk

Like0
Dislike0

Emerging mRNA Vaccine Technologies Transforming the Global Animal Vaccines Market 2021-2033

Like0
Dislike0

Insights into Canine Idiopathic Rhinitis from a Prospective Study: A Multimodal Diagnostic Perspective.

Like0
Dislike0

No light, no problem: provision of light during simulated transport does not alter broiler chick performance or welfare outcomes.

Like0
Dislike0

Chronic Kidney Disease in Cats

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top